

31 March 2011
EMA/HMPC/688215/2008
Committee on Herbal Medicinal Products (HMPC)

List of references supporting the assessment of *Echinacea angustifolia* DC., radix

Draft

The Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Agnew LL, Guffogg SP, Matthias A, Lehmann RP, Bone KM, Watson K (2005). *Echinacea* intake induces an immune response through altered expression of leucocyte hsp70, increased white cell counts and improved erythrocyte antioxidant defences. *J Clin Pharm Ther* 30: 363-369.

Barnes J, Anderson, LA, Gibbons S, Phillipson JD (2005). *Echinacea* species (*Echinacea angustifolia* (DC.) Hell., *Echinacea pallida* (Nutt.) Nutt., *Echinacea purpurea* (L.) Moench): A review of their chemistry, pharmacology and clinical properties. *J Pharm Pharmacol* 57: 929-954.

Barnes J, Anderson LA, Phillipson JD (2007). *Echinacea*. In: *Herbal Medicines*, 3rd ed., Pharmaceutical Press, London, UK: 217-236.

Barrett B, Brown RL, Locken K, Maberry R, Bobula JA, D'Alessio D (2002). Treatment of the common cold with unrefined *Echinacea*. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 137: 939-946.

Barrett B (2003). Medicinal properties of *Echinacea*: a critical review. *Phytomedicine* 10: 66-86.

Basch E, Ulbricht C, Basch S, Dalton S, Ernst E, Foppa I, Szapary P, Tiffany N, Orlando CW, Vora M (2005). An evidence-based systemic review *Echinacea* *E. angustifolia* DC, *E. pallida*, *E. purpurea* by the Natural Standard Research Collaboration. *J Herb Pharmacother* 5: 57-88.

Bauer R, Jurcic K, Puhlmann J, Wagner H (1988a). Immunologische *In-vivo*- und *In-vitro*-Untersuchungen mit *Echinacea*-Extrakten. *Arzneim Forsch* 38: 276-281.

Bauer R, Khan IA, Wagner H (1988b). TLC and HPLC Analysis of *Echinacea pallida* and *E. angustifolia* roots. *Planta Med* 54: 426-430.

Bauer R, Remiger P (1989a). TLC and HPLC Analysis of Alkamides in *Echinacea* Drugs. *Planta Med* 55: 367-371.

- Bauer R, Remiger P, Jurcic K, Wagner H (1989b) Beeinflussung der Phagozytose-Aktivitat durch *Echinacea*-Extrakte. *Z Phytother* 10: 43-48.
- Beuscher N, Bodinet I, Willigmann D, Egert (1995). Immonomodulierende Eigenschaften von Wurzelextrakten verschiedenen *Echinacea*-Arten. *Z Phytother* 16: 157-166.
- Binns SE, Purgina B, Bergeron C, Smith ML, Ball L, Baum BR, Arnason JT (2000). Light-mediated antifungal activity of *Echinacea* extracts. *Planta Med* 66: 241-244.
- Binns SE, Hudson J, Merali S, Arnason JT (2002). Antiviral activity of characterized extracts from *Echinacea* spp. (Heliantheae: Asteraceae) against herpes simplex virus (HSV-1). *Planta Med* 68: 780-783.
- Blumenthal M, Goldberg A, Brinckmann J (2000). *Echinacea angustifolia* herb and root. In: Herbal medicine - Expanded Commission E monographs CD-ROM. American Botanical Council, Integrative Medicine Communications Inc., Newton, MA, USA.
- Blumenthal M (2005). *Echinacea angustifolia* in rhinovirus infections. *N Engl J Med* 353: 1971-1972.
- Bradley P (2006). *Echinacea*. In: British Herbal Compendium, Vol. 2., British Herbal Medicine Association, Bournemouth, UK: 129-141.
- Budzinski JW, Foster BC, Vandenhoeck S, Arnason JT (2000). An *in vitro* evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. *Phytomedicine* 7: 273-282.
- Chen Y, Fu T, Tao T, Yang J, Chang Y, Wang M, Kim L, Qu L, Cassady J, Scalzo R, Wang X (2005). Macrophage Activating Effects of New Alkamides from the Roots of *Echinacea* Species. *J Nat Prod* 68: 773-776.
- Chicca A, Adinolfi B, Martinotti E, Fogli S, Breschi MC, Pellati F, Benvenuti S, Nieri P (2007). Cytotoxic effects of *Echinacea* root hexanic extracts on human cancer cell lines. *J Ethnopharmacol* 110: 148-153.
- Chicca A, Pellati F, Adinolfi B, Matthias A, Massarelli I, Benvenuti S, Martinotti E, Bianucci AM, Bone K, Lehmann R, Nieri P (2008). Cytotoxic activity of polyacetylenes and polyenes isolated from roots of *Echinacea pallida*. *Br J Pharmacol* 153: 879-885.
- Cohen HA, Varsano I, Kahan E, Sarrell EM, Uziel Y (2004). Effectiveness of an herbal preparation containing *Echinacea*, propolis, and vitamin C in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled, multicenter study. *Arch Pediatr Adolesc Med* 158: 217-221.
- Cozzolino R, Malvagna P, Spina E, Giori A, Fuzzati N, Anelli A, Garozzo D, Impallomeni G (2006). Structural analysis of the polysaccharides from *Echinacea angustifolia* radix. *Carbohydr Polym* 65: 263-272.
- Ellingwood F (1915). *Echinacea angustifolia*. In: *American Materia Medica, Therapeutics and Pharmacognosy*, Ellingwood's Therapeutics, Evanston, IL, USA: 358-367.
- European Pharmacopoeia (2008). Narrow-leaved Coneflower Root. In: *European Pharmacopoeia*, 6.0., Vol. 2, European Directorate for the Quality of Medicines, Strasbourg, France: 5064-5066.
- European Scientific Cooperative On Phytotherapy (ESCOP) (2009). *Echinaceae angustifoliae radix*. In: *ESCOP Monographs*, 2nd ed., Suppl. 2009 Thieme, New York, NY, USA: 81-86.
- Fearn J (1914). *Echinacea*. *Eclect Med J* 74: 177-181.
- Felter HW (1898). The Newer Materia Medica. I. *Echinacea*. *Eclect Med J* 58: 79-89.

- Felter HW, Lloyd JU (1905). *Echinacea*. In: *King's American Dispensatory*, The Ohio Walley Company, Cincinnati, OH, USA: 671-677.
- Flannery MA (1999). From *Rudbeckia* to *Echinacea*: The Emergence of the Purple Cone Flower in Modern Therapeutics. *Pharmacy in History* 41: 52-59.
- Freeman C, Spelman K (2008). A critical evaluation of drug interactions with *Echinacea* spp. *Mol Nutr Food Res* 52: 789-798.
- Fyfe JW (1909). *Echinacea angustifolia* – Hedge-hog Cane Flower. In: *Specific Diagnosis and Specific Medication*, The Scudder Brothers Company, Cincinnati, OH, USA: 506-512.
- Gallo M, Sarkar M, Au W, Pietrzak K, Comas B, Smith M, Jaeger TV, Einarson A, Koren G (2000). Pregnancy outcome following gestational exposure to *Echinacea*: a prospective controlled study. *Arch Intern Med* 160(20): 3141-3143.
- Gertsch J, Schoop R, Kuenzle U, Suter A (2004). *Echinacea* alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. *FEBS Lett* 577: 563-569.
- Gilmore MR (1919). *Echinacea angustifolia*. In: *Uses of Plants by the Indians of the Missouri River Region*, Government printing Office, Washington, USA: 131.
- Goel V, Chang C, Slama J, Barton R, Bauer R, Gahler R, Basu T (2002a). *Echinacea* stimulates macrophage function in the lung and spleen of normal rats. *J Nutr Biochem* 13: 487-492.
- Goel V, Chang C, Slama JV, Barton R, Bauer R, Gahler R, Basu TK (2002b). Alkylamides of *Echinacea purpurea* stimulate alveolar macrophage function in normal rats. *Int Immunopharmacol* 2: 381-387.
- Goss JM (1889). *Echinacea angustifolia*. In: *A Textbook of Materia Medica, Pharmacology and Special Therapeutics*, 2nd ed. W. T. Keener, Chicago, IL, USA: 73-74.
- Gryzlak BM, Wallace RB, Zimmerman MB, Nisly NL (2007). National surveillance of herbal dietary supplement exposures: the poison control center experience. *Pharmacoepidemiol Drug Saf* 16: 947-957.
- Haller CA, Anderson IB, Kim SY, Blanc PD (2002). An evaluation of selected herbal reference texts and comparison to published reports of adverse herbal events. *Adverse Drug React Toxicol Rev* 21: 143-150.
- Hinz B, Woelkart K, Bauer R (2007). Alkamides from *Echinacea* inhibit cyclooxygenase-2 activity in human neuroglioma cells. *Biochem Bioph Res Co* 360: 441-446.
- Hocking GM (1965). *Echinacea angustifolia* (Cone Flower) as Crude Drug. *Q J Crude Drug Res* 5: 679-682.
- Hu C, Kitts DD (2000). Studies on the antioxidant activity of *Echinacea* root extract. *J Agric Food Chem* 48: 1466-72.
- Huntley AL, Thompson Coon J, Ernst E (2005). The safety of herbal medicinal products derived from *Echinacea* species: a systematic review. *Drug Saf* 28: 387-400.
- Islam J, Carter R (2005). Use of *Echinacea* in upper respiratory tract infection. *South Med J* 98: 311-318.
- Jager H, Meinel L, Dietz B, Lapke C, Bauer R, Merkle HP, Heilmann J (2002). Transport of Alkamides from *Echinacea* Species through Caco-2 Monolayers. *Planta Medica* 68: 469-471.

Jensen J, Halaweish FT (2006). Studies of *Echinacea* on HeLa and MCF-7 cancer cell lines. In: Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, USA.

Jensen J, Halaweish FT, Chase C (2007). Interference of *Echinacea* on cancer chemotherapy. In: Abstracts of Papers, 234th ACS National Meeting, Boston, MA, USA.

Kim LS, Waters RF, Burkholder PM (2007). Immunological activity of larch arabinogalactan and *Echinacea*: a preliminary, randomized, double-blind, placebo-controlled trial. *Altern Med Rev* 7: 138-149.

Kindscher K (1989). Ethnobotany of purple coneflower (*Echinacea angustifolia*, Asteraceae) and Other *Echinacea* Species. *Econ Bot* 43: 498-507.

Kraemer H, Sollenberger M (1911). The Pharmacognocny of *Echinacea*. *Am J Pharm* 83: 315-325.

LaLone CA, Hammer KD, Wu L, Bae J, Leyva N, Liu Y, Solco AK, Kraus GA, Murphy PA, Wurtele ES, Kim OK, Seo KI, Widrlechner MP, Birt DF (2007). *Echinacea* species and alkamides inhibit prostaglandin E(2) production in RAW264.7 mouse macrophage cells. *J Agric Food Chem* 55: 7314-7322.

Leach M (2005). *Echinacea angustifolia* in rhinovirus infections. *N Engl J Med* 353: 1971-1972.

Liebstein AM (1927). Therapeutic Action of *Echinacea*. *Eclect Med J* 87: 316-320.

Liersch R, Bauer R (1993). *Echinacea*. In: Hagers Buch der Pharmazeutischen Praxis, 5th ed., Vol. 5: Drogen E-O, Springer-Verlag, Berlin, Germany: 1-34.

Linde K, Barret B, Bauer R, Melchart D, Woelkart K (2006). *Echinacea* for preventing and treating the common cold. *Cochrane Database of Systematic Reviews*, Issue 1, In: The Cochrane Library 2008, Issue 3, John Wiley & Sons, Ltd., Chichester, UK: 1-88.

Lloyd JU (1904a). History of *Echinacea angustifolia*. *Pharm Rev* 22: 9-14.

Lloyd JU (1904b). History of *Echinacea angustifolia*. *Am J Pharm* 22: 15-19.

Lloyd JU (1917). *Echinacea angustifolia* – History, description and Adulterations. *Ellingwood's Therapeutist* 11: 101-120.

Lloyd JU (1923). *Echinacea*, Lloyd Brothers, Cincinnati, OH, USA.

Maffei Facino R, Carini M, Aldini G, Saibene L, Pietta P, Mauri P (1995). Echinacoside and caffeoyl conjugates protect collagen from free radical-induced degradation: a potential use of *Echinacea* extracts in the prevention of skin photodamage. *Planta Med* 61: 510-514.

Matthias A, Blanchfield JT, Penman KG, Toth I, Lang CS, De Voss JJ, Lehmann RP (2004). Permeability studies of alkylamides and caffeic acid conjugates from *Echinacea* using a Caco-2 cell monolayer model. *J Clin Pharm Ther* 29: 7-13.

Matthias A, Gillam EM, Penman KG, Matovic NJ, Bone KM, De Voss JJ, Lehmann RP (2005a). Cytochrome P450 enzyme-mediated degradation of *Echinacea* alkylamides in human liver microsomes. *Chem Biol Interact* 155: 62-70.

Matthias A, Addison RS, Penman KG, Dickinson RG, Bone KM, Lehmann RP (2005b). *Echinacea* alkamide disposition and pharmacokinetics in humans after tablet ingestion. *Life Sci* 77: 2018-2029.

Matthias A, Penman KG, Matovic NJ, Bone KM, De Voss JJ, Lehmann RP (2005c). Bioavailability of *Echinacea* constituents: Caco-2 monolayers and pharmacokinetics of the alkylamides and caffeic acid conjugates. *Molecules* 10: 1242-1251.

- Matthias A, Banbury L, Stevenson LM, Bone KM, Leach DN, Lehmann RP (2007a). Alkylamides from *Echinacea* modulate induced immune responses in macrophages. *Immunol Invest* 36: 117-130.
- Matthias A, Addison RS, Agnew LL, Bone KM, Watson K, Lehmann RP (2007b). Comparison of *Echinacea* alkylamide pharmacokinetics between liquid and tablet preparations. *Phytomedicine* 14: 587-590.
- Matthias A, Banbury L, Bone KM, Leach DN, Lehmann RP (2008). *Echinacea* alkylamides modulate induced immune responses in T-cells. *Fitoterapia* 79: 53-58.
- Mazza G, Cottrell T (1999). Volatile components of roots, stems, leaves, and flowers of *Echinacea* species. *J Agric Food Chem* 47: 3081-3085.
- McCann DA, Solco A, Liu Y, Macaluso F, Murphy PA, Kohut ML, Senchina DS (2007). Cytokine- and interferon-modulating properties of *Echinacea* spp. root tinctures stored at -20°C for 2 years. *J Interferon Cytokine Res* 27: 425-436.
- Meijerman I, Beijnen JH, Schellens JH (2006). Herb-drug interactions in oncology: focus on mechanisms of induction. *Oncologist* 11: 742-752.
- Melchart D, Linde K., Worku F, Bauer R, Wagner H (1994). Immunomodulation with *Echinacea*. A systematic review of controlled clinical trials. *Phytomed* 1: 245-254.
- Melchart D, Linde K, Worku F, Sarkady L, Holzmann M, Jurcic K, Wagner H (1995). Results of five randomized studies on the immunomodulatory activity of preparations of *Echinacea*. *J Altern Complement Med* 1: 145-160.
- Melchart D, Walther E, Linde K, Brandmaier R, Lersch C (1998). *Echinacea* root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial. *Arch Fam Med* 7: 541-545.
- Melchart D, Linde K (1999). Clinical Investigations of *Echinacea* Phytopharmaceuticals. In: *Immunomodulatory Agents from Plants*, Birkhäuser Verlag, Basel, Switzerland: 105-118.
- Melchart D, Linde K, Fischer P, Kaesmayr J (2004). *Echinacea* for preventing and treating the common cold (Cochrane review). In: *The Cochrane Library*, Issue 2, John Wiley & Sons, Chichester, UK.
- Merali S, Binns S, Paulin-Levasseur M, Ficker C, Smith M, Baum B, Brovelli E, Arnason JT (2003). Antifungal and Anti-inflammatory Activity of the Genus *Echinacea*. *Pharmaceutical Biology* 41: 412-420.
- Meyer HCF (1887). *Echinacea angustifolia*. *Eclect Med J* 57: 209-210.
- Morazzoni P, Cristoni A, Di Pierro F, Avanzini C, Ravarino D, Stornello S, Zucca M, Musso T (2005). *In vitro* and *in vivo* immune stimulating effects of a new standardized *Echinacea angustifolia* root extract (Polinacea). *Fitoterapia* 76: 401-411.
- Müller-Jakic B, Breu W, Pröbstle A, Redl K, Greger H, Bauer R (1994). *In vitro* inhibition of cyclooxygenase and 5-lipoxygenase by alkamides from *Echinacea* and *Achillea* species. *Planta Med* 60: 37-40.
- National Formulary (1916). *Echinacea*. In: *National Formulary*, 4th ed., American Pharmaceutical Association, USA: 294.
- Niederkorn JS (1910). *Echinacea* in the Treatment of the Bites of Venomous Serpents, Reptiles and Insects, Lloyd Brothers, Cincinnati, OH, USA.
- PDR for herbal medicines 4th Edition (2007). *Echinacea*. Thomson healthcare Inc. NJ, USA: 266-276.

- Pellati F, Benvenuti S, Magro L, Melegari M, Soragni F (2004). Analysis of phenolic compounds and radical scavenging activity of *Echinacea* spp. J Pharm Biomed Anal 35: 289-301.
- Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, Altmann KH, Gertsch J (2006). Alkylamides from *Echinacea* are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem 281: 14192-14206.
- Perry NB, Burgess EJ, Glennie VL (2001). *Echinacea* standardization: analytical methods for phenolic compounds and typical levels in medicinal species. J Agric Food Chem 49: 1702-1706.
- Perri D, Dugoua JJ, Mills E, Koren G. (2006) Safety and efficacy of *Echinacea* (*Echinacea angustifolia*, *E. purpurea* and *E. pallida*) during pregnancy and lactation. Can J Clin Pharmacol. 13(3): 262-267.
- Price DM, Kindscher K (2007). One Hundred Years of *Echinacea angustifolia* Harvest in the Smoky Hills of Kansas, USA. Econ Bot 61: 86-95.
- Rehman J, Dillow JM, Carter SM, Chou J, Le B, Maisel AS (1999). Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants *Echinacea angustifolia* and *Hydrastis canadensis*. Immunol Lett 68: 391-395.
- Romiti N, Pellati F, Nieri P, Benvenuti S, Adinolfi B, Chieli E (2008). P-Glycoprotein inhibitory activity of lipophilic constituents of *Echinacea pallida* roots in a human proximal tubular cell line. Planta Med 74: 264-266.
- Schoop R, Klein P, Suter A, Johnston SL (2006). *Echinacea* in the prevention of induced rhinovirus colds: a meta-analysis. Clin Ther 28: 174-183.
- Senchina DS, McCann DA, Asp JM, Johnson JA, Cunnick JE, Kaiser MS, Kohut ML (2005). Changes in immunomodulatory properties of *Echinacea* spp. root infusions and tinctures stored at 4 degrees C for four days. Clin Chim Acta 355: 67-82.
- Senchina DS, Wu L, Flinn GN, Konopka del N, McCoy JA, Widrlechner MP, Wurtele ES, Kohut ML (2006). Year-and-a-half old, dried *Echinacea* roots retain cytokine-modulating capabilities in an *in vitro* human older adult model of influenza vaccination. Planta Med 72: 1207-1215.
- Senchina DS, Flagel LE, Wendel JF, Kohut ML (2008). Phenetic comparison of seven *Echinacea* species based on immunomodulatory characteristics. Econ Bot 60: 205-211.
- Shah SA, Sander S, White CM, Rinaldi M, Coleman CI (2007). Evaluation of *Echinacea* for the prevention and treatment of the common cold: a meta-analysis. Lancet Infect Dis 7: 473-480.
- Sharma M, Arnason JT, Burt A, Hudson JB (2006). *Echinacea* extracts modulate the pattern of chemokine and cytokine secretion in rhinovirus-infected and uninfected epithelial cells. Phytother Res 20: 147-152.
- Skwarek T, Tynecka Z, Glowniak K, Lutostanska E (1996). *Echinacea* L. – Inducer of interferons. Herba Polonica 42: 110-117.
- Sloley BD, Urichuk LJ, Tywin C, Coutts RT, Pang PK, Shan JJ (2001). Comparison of chemical components and antioxidants capacity of different *Echinacea* species. J Pharm Pharmacol 53: 849-857.
- Smith HH (1928). Narrow-leaved Purple Cone-flower. In: *Ethnobotany of the Meskwaki Indians*, Order of the Board Trustees, Milwaukee, WI, USA: 194, 212.
- South EH, Exon JH (2001). Multiple immune functions in rats fed *Echinacea* extracts. Immunopharmacol Immunotoxicol 23: 411-421.

Starvaggi Cucuzza L, Motta M, Accornero P, Baratta M (2008). Effect of *Echinacea angustifolia* extract on cell viability and differentiation in mammary epithelial cells. *Phytomedicine* 15: 555-562.

Stevens JV (1898). *Echinacea*. *Ann Eclect Med Surg* 8: 347-349.

Tragni E, Tubaro A, Melis S, Galli CL (1985). Evidence from two classic irritation tests for an anti-inflammatory action of a natural extract, Echinacina B. *Food Chem Toxicol* 23: 317-319.

Tragni E, Galli CL, Tubaro A, Del Negro P, Della Loggia R (1988). Anti-inflammatory activity of *Echinacea angustifolia* fractions separated on the basis of molecular weight. *Pharmacol Res Commun Suppl* 5: 87-90.

Tubaro A, Tragni E, Del Negro P, Galli CL, Della Loggia R (1987). Anti-inflammatory activity of a polysaccharidic fraction of *Echinacea angustifolia*. *J Pharm Pharmacol* 39: 567-569.

Turner RB, Bauer R, Woelkart K, Hulsey TC, Gangemi JD (2005). An evaluation of *Echinacea angustifolia* in experimental rhinovirus infections. *N Engl J Med* 353: 341-348.

Vestal PA, Schultes RE (1939). *Brauneria angustifolia*. In: *The economic Botany of the Kiowa Indians*, Botanical Museum, Cambridge, MA, USA: 57-58.

Voaden DJ, Jacobson M (1972). Tumor Inhibitors. 3. Identification and Synthesis of an Oncolytic Hydrocarbon from American Coneflower Roots. *J Med Chem* 15: 619-623.

Wagner H, Proksch A, Riess-Maurer I, Vollmar A, Odenthal S, Stuppner H, Jurcic K, Le Turdu M, Fang JN (1984). Immunostimulating action of polysaccharides (heteroglycans) from higher plants. *Arzneim Forsch* 35: 1069-1075.

Wagner H, Breu W, Willer F, Wierer M, Remiger P, Schwenker G (1989). *In vitro* inhibition of arachidonate metabolism by some alkamides and prenylated phenols. *Planta Med* 55: 566-567.

Wagner H, Jurcic K (1991). Immunologic studies of plant combination preparations. *In-vitro* and *in-vivo* studies on the stimulation of phagocytosis. *Arzneim Forsch* 41: 1072-1076.

Webster HT (1898). *Echinacea angustifolia*. In: *Dynamical Therapeutics*, 2nd ed., Webster Medical Publishing Company, San Francisco, CA, USA: 69-75.

Woelkart K, Xu W, Pei Y, Makriyannis A, Picone RP, Bauer R (2005a). The endocannabinoid system as a target for alkamides from *Echinacea angustifolia* roots. *Planta Med* 71: 701-705.

Woelkart K, Koidl C, Grisold A, Gangemi JD, Turner RB, Marth E, Bauer R (2005b). Bioavailability and pharmacokinetics of alkamides from the roots of *Echinacea angustifolia* in humans. *J Clin Pharmacol* 45: 683-689.

Woelkart K, Bauer R (2007). The role of alkamides as an active principle of *Echinacea*. *Planta Med* 73: 615-623.

Wolters Kluwer Health (2004). *Echinacea*. In: *The Review of Natural Products*, Wolters Kluwer Health, St. Luis, MO, USA.

Zhai Z, Liu Y, Wu L, Senchina DS, Wurtele ES, Murphy PA, Kohut ML, Cunnick JE (2007a). Enhancement of innate and adaptive immune functions by multiple *Echinacea* species. *J Med Food* 10: 423-434.

Zhai Z, Haney D, Wu L, Solco A, Murphy PA, Wurtele ES, Kohut ML, Cunnick JE (2007b). Alcohol extracts of *Echinacea* inhibit production of nitric oxide and tumor necrosis factor-alpha by macrophages *in vitro*. *Food Agric Immunol* 18: 221-236.

Zhang Y, Xing J, Ai T, Wen T, Guan L, Zhao J (2007). Protection of echinacoside against acute lung injury caused by oleic acid in rats. Free Radic Res 41: 798-805.